GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pliant Therapeutics Inc (NAS:PLRX) » Definitions » 1-Year ROIIC %

Pliant Therapeutics (Pliant Therapeutics) 1-Year ROIIC % : -247.72% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Pliant Therapeutics 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Pliant Therapeutics's 1-Year ROIIC % for the quarter that ended in Mar. 2024 was -247.72%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Pliant Therapeutics's 1-Year ROIIC % or its related term are showing as below:

PLRX's 1-Year ROIIC % is ranked worse than
80.76% of 1450 companies
in the Biotechnology industry
Industry Median: -3.625 vs PLRX: -247.72

Pliant Therapeutics 1-Year ROIIC % Historical Data

The historical data trend for Pliant Therapeutics's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pliant Therapeutics 1-Year ROIIC % Chart

Pliant Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
1-Year ROIIC %
Get a 7-Day Free Trial 623.88 -7,986.96 -776.36 -2,696.82 1,932.30

Pliant Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,717.26 -9,572.96 1,621.50 1,932.30 -247.72

Competitive Comparison of Pliant Therapeutics's 1-Year ROIIC %

For the Biotechnology subindustry, Pliant Therapeutics's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pliant Therapeutics's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pliant Therapeutics's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Pliant Therapeutics's 1-Year ROIIC % falls into.



Pliant Therapeutics 1-Year ROIIC % Calculation

Pliant Therapeutics's 1-Year ROIIC % for the quarter that ended in Mar. 2024 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -194.442 (Mar. 2024) - -141.084 (Mar. 2023) )/( 37.021 (Mar. 2024) - 15.481 (Mar. 2023) )
=-53.358/21.54
=-247.72%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Pliant Therapeutics  (NAS:PLRX) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Pliant Therapeutics 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Pliant Therapeutics's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pliant Therapeutics (Pliant Therapeutics) Business Description

Traded in Other Exchanges
Address
260 Littlefield Avenue, South San Francisco, CA, USA, 94080
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Executives
Hans Hull officer: Chief Business Officer C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Eric Lefebvre officer: Chief Medical Officer C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Keith Lamont Cummings officer: Chief Financial Officer C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Bernard Coulie director, officer: President and CEO C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Mike Ouimette officer: General Counsel C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Thomas A Mccourt director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Lily Cheung officer: Chief Human Resource Officer 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Katharine Knobil director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612
Third Rock Ventures Gp Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Kevin P Starr 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Smital Shah director C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129

Pliant Therapeutics (Pliant Therapeutics) Headlines

From GuruFocus

Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer

By Stock market mentor Stock market mentor 01-25-2023

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering

By Stock market mentor Stock market mentor 01-25-2023

Pliant Therapeutics to Participate in Upcoming Investor Events

By Stock market mentor Stock market mentor 02-07-2023